Paper Details

  1. Home
  2. Paper Details

Botulinum toxins for the prevention of migraine in adults.

Author: ClarkeCarl E, EdwardsJulie, HerdClare P, IvesNatalie, RickCaroline, ScottonW J, SinclairAlexandra, TomlinsonClaire L

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Migraine is a common and disabling condition, affecting around 15% of adults. While treatments can help, many people still experience frequent and severe headaches. Botulinum toxin type A has been approved in some countries for chronic migraine, which is defined as 15 or more headache days per month, with at least 8 of those being migraines. This approval was based on just two studies, highlighting the need for more research.
Paper Details　
Original Abstract of the Article :
Migraine occurs in around 15% of adults and is ranked as the seventh most disabling disease amongst all diseases globally. Despite the available treatments many people suffer prolonged and frequent attacks which have a major impact on their quality of life. Chronic migraine is defined as 15 or more ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513576/

データ提供：米国国立医学図書館（NLM）

Botulinum Toxin: A New Path for Migraine Treatment

The relentless onslaught of migraine headaches can be a debilitating experience, leaving individuals navigating a treacherous landscape of pain and discomfort. This study explores the potential of botulinum toxin type A as a novel treatment option for migraine. The researchers highlight the widespread prevalence of migraine and the significant impact it has on quality of life. They note that while traditional treatments exist, many individuals continue to experience frequent and prolonged attacks. This study explores the potential of botulinum toxin type A as a new path for managing migraine, particularly for individuals experiencing chronic migraine.

Seeking a Sustainable Solution

This study's focus on botulinum toxin type A for migraine treatment, particularly for those experiencing chronic migraine, offers a glimmer of hope for individuals seeking relief from this debilitating condition. The research findings suggest a potential for botulinum toxin type A to offer a more sustainable solution for managing migraine, potentially reducing the frequency and severity of attacks.

Navigating the Landscape of Migraine

As Dr. Camel, I'm always seeking new paths through the desert of chronic pain. The potential of botulinum toxin type A for migraine treatment is exciting, It reminds me of finding a hidden spring in the middle of a barren desert, a source of relief and hope. I encourage further research into this treatment option for migraine.

Dr.Camel's Conclusion

This study delves into the potential benefits of botulinum toxin type A for treating migraine, particularly for those experiencing chronic migraine. The research findings offer a glimmer of hope for individuals seeking relief from this debilitating condition. Further research is needed to fully understand the efficacy and safety of this treatment option.

Date :
  1. Date Completed 2018-07-20
  2. Date Revised 2022-08-13
Further Info :

Pubmed ID

29939406

DOI: Digital Object Identifier

PMC6513576

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.